Jeffrey Epstein Finances New Technology for Detecting Metastatic Cancer through Breast Cancer Research. Thanks to funding from The Jeffrey Epstein VI Foundation new breast cancer research has uncovered techniques that could lead to early detection of Metastatic Cancer. Early detection is crucial due to the fact that most patients who die from cancer die from Metastatic Cancer, a cancer that has spread from the origin to another system in the body. Metastatic Cancer most commonly causes bone, liver, and lung cancer. When tumors are removed before metastasis the 5-year relative survival rate is 99%. The rate lowers to 84% when it spread to the breasts and hits a staggering 23% once metastasis enters the blood stream. In order to achieve successful long-term survival early detection is vital. A research team led by Mount Sinai surgeon Dr. Jess Ting including molecular biologist Doris Germain, and breast oncologist Dr. Kerin Adelson have discovered that tumor's create a micro-environment in the body. Traditionally scientists have used patient's blood to analyze disease related biomarkers. Unfortunately blood's complex composition makes it difficult to glean information specific to the cancer in our bodies. The discovery of a tumor's micro -environment allows scientist to uncover the specific proteins, cytokines, and growth factors that are secreted by cells around the cancer source, these biomarkers are specific to the tumor and provide valuable prognostic information on disease progression. Dr. Ting's team discovered the micro- environments by analyzing the fluid emitted from a post surgery wound site. The wound fluid, collected via draining tubes, contained all the proteins, growth factors and cytokines that were secreted by the cells around the cancer creating an ideal environment to study the cancer in vivo. Wound fluid from a breast cancer patient has a tremendous advantage of having an exact control specimen since both breasts are usually